Literature DB >> 25585653

[Isoflurane-induced malignant hyperthermia during intensive-care treatment].

B Wendlandt1, S Turinsky, M Schmitz.   

Abstract

Malignant hyperthermia (MH), an inherited myopathia varying in severity and course, is induced by halogenated anesthetic agents and depolarizing muscle relaxants. First recognized as a distinct disease entity in 1960, MH is defined as an anesthesia-related disease due to the agents by which it is triggered. Given the wide use of these preparations in prehospital emergency medicine and intensive care treatment, physicians in other disciplines may also encounter MH.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25585653     DOI： 10.1007/s00063-014-0450-4

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN： 2193-6218            Impact factor:   0.840


  4 in total

1.  Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group.

Authors:  K P E Glahn; F R Ellis; P J Halsall; C R Müller; M M J Snoeck; A Urwyler; F Wappler
Journal:  Br J Anaesth       Date:  2010-10       Impact factor: 9.166

2.  Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.

Authors:  Marilyn Green Larach; Gerald A Gronert; Gregory C Allen; Barbara W Brandom; Erik B Lehman
Journal:  Anesth Analg       Date:  2010-02-01       Impact factor: 5.108

3.  Malignant hyperthermia. An historical vignette.

Authors:  G G Harrison; H Isaacs
Journal:  Anaesthesia       Date:  1992-01       Impact factor: 6.955

Review 4.  The genetics of malignant hyperthermia.

Authors:  S P Ball; K J Johnson
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.